Matthew B. Yurgelun, MD

Recent years have brought tremendous progress in demonstrating that there is hope for improving mortality from pancreatic ductal adenocarcinoma through early detection.

Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.

Matthew B. Yurgelun, MD, assistant professor of Medicine, Harvard Medical School, and a researcher at the Dana-Farber Cancer Institute, discusses germline testing in colorectal cancer.

Matthew B. Yurgelun, MD, Targeted Oncology, Yurgelun, Instructor in Medicine, Harvard Medical School, discusses a recent study which uncovered BRCA1 and BRCA2 mutations as possible risk markers for colorectal cancer.